Hyperion DeFi Inc(HYPD) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -3.44 | Insider Own | 17.53% | Shs Outstand | 15.3M | Perf Week | -3.23% |
| Market Cap | 0.05B | Forward P/E | 1.24 | EPS next Y | -65.43% | Insider Trans | 0.29% | Shs Float | 12.8M | Perf Month | -24.81% |
| Enterprise Value | 0.05B | PEG | - | EPS next Q | 2.31 | Inst Own | 17.12% | Short Float | 10.11% | Perf Quarter | 12.78% |
| Income | -0.02B | P/S | 33.3 | EPS this Y | 174.47% | Inst Trans | -0.63% | Short Ratio | 2.84 | Perf Half Y | -24.24% |
| Sales | 0.00B | P/B | 0.45 | EPS next 5Y | - | ROA | 7.88% | Short Interest | 1.30M | Perf YTD | -15.73% |
| Book/sh | 6.66 | P/C | 4.84 | EPS past 3/5Y | 47.93% 34.01% | ROE | 9.55% | 52W High | -67.14% ($9.13) | Perf Year | -63.33% |
| Cash/sh | 0.62 | P/FCF | - | Sales past 3/5Y | - -16.47% | ROIC | 6.18% | 52W Low | 28.21% ($2.34) | Perf 3Y | -96.53% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 89.91% | Gross Margin | - | Volatility(W/M) | 6.51% 6.49% | Perf 5Y | -99.05% |
| Dividend TTM | - | EV/Sales | 32.78 | Sales Y/Y TTM | 3052.03% | Oper. Margin | -1095.7% | ATR (14) | 0.23 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 2.34 | EPS Q/Q | 136.97% | Profit Margin | -1528.45% | RSI (14) | 42.99 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.34 | Sales Q/Q | - | SMA20 | -7.49% ($3.24) | Beta | 2.73 | Target Price | $10.22 |
| Payout | - | Debt/Eq | 0.09 | Earnings | 2026/11/12 | SMA50 | -12.21% ($3.42) | Rel Volume | 0.51 | Prev Close | $2.99 |
| Employees | 9 | LT Debt/Eq | 0.06 | EPS/Sales Surpr. | -58.93% -71.76% | SMA200 | -10.71% ($3.36) | Avg Volume(3M) | 0.46M | Price | $3 |
| IPO | 2018/1/25 | Option/Short | No/Yes | Trades | 1008 | Volume | 233,159 | Change | 0.33% |
🌳 Hyperion DeFi () is a NASDAQ-listed company that converted from the existing ophthalmic medical device company Eyenovia by changing its name and ticker to transition into a cryptocurrency-focused business. It holds and stakes HYPE tokens from the Hyperliquid protocol as part of its treasury and operates on-chain options-based yield products.
Over the past 1 year, on the lower side
67% below its 1-year high.
Traded less than usual. That is 51% of its average volume.
Next earnings report: November 12
14 days to go.
HYPD has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +174.5% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $3,330. Peers typically go for $1,089.
Tap to view numbers
Not enough quarters to judge yet
Only 2 quarter(s) reported, so no grade yet.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -99.0%. The S&P 500 did +69% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 17.1%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #423 of 594 in the industry
Based on market cap of $47M.
MREO#420 Mereo Biopharma Group Plc ADR $47M PER - 
BMEA#421 Biomea Fusion Inc $47M PER - 
LONA#422 LeonaBio Inc $47M PER - HYPD#423 Hyperion DeFi Inc $47M PER - 
TIL#424 Instil Bio Inc $46M PER - 
FAQ
What kind of company is HYPD?
HYPD belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of HYPD?
The market cap of HYPD is approximately $47M, ranking 4,888 within its sector.
What is the 52-week high and low for HYPD?
HYPD has recorded a 52-week high of $9.13 and a low of $2.34.
